Actively Recruiting
Phase 1 Study of GTB-3650 Tri-Specific Killer Engager for Treating High Risk Myelodysplastic Syndromes and Relapsed or Refractory Acute Myeloid Leukemia in Adults
Led by Masonic Cancer Center, University of Minnesota · Updated on 2026-07-14
45
Participants Needed
1
Research Sites
30 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating GTB-3650, a Tri-Specific Killer Engager TriKE4 targeting CD33-expressing myeloid malignancies such as high-risk myelodysplastic syndromes MDS and refractoryrelapsed acute myeloid leukemia AML in adults aged 18 and older. This Phase I dose-finding study focuses on patients who are not candidates for curative therapies like stem cell transplantation and have limited treatment options. The drug aims to stimulate natural killer NK cell activity to target malignant cells and suppress immune-suppressing myeloid cells. GTB-3650 is given by continuous infusion during inpatient stays in 72-hour periods called blocks, with three consecutive 24-hour infusions per block. Two blocks make up a 28-day treatment cycle, followed by about 18 days without treatment. Patients may receive up to four cycles if they meet safety and response criteria. The study includes multiple dose levels to find the maximum tolerated dose. Participants will be closely monitored with safety assessments before each treatment block and throughout the study. The research team will measure the maximum tolerated dose, adverse events, event-free survival, and overall survival over six months. This careful monitoring helps ensure patient safety and evaluate the drugs effects during and after treatment, with the entire study expected to last until 2027.
CONDITIONS
Brief Title
HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML
Research Team
M
Mark Juckett, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here